The grants, totaling 35,275 restricted stock units, function as a standard incentive for incoming personnel. According to the company, these awards are structured to vest over a four-year period, with 25% of the total grant maturing annually. This move aligns with the biotech firm's ongoing efforts to bolster its workforce as it continues its research into hematologic disorders and oncology therapies. Rigel, which has operated out of South San Francisco since its founding in 1996, remains focused on the development of novel clinical treatments for chronic conditions.